A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic Infertility (Unexplained Reduction of Semen Quality) (ADAM)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The primary purpose of this trial is to investigate whether men with idiopathic infertility (unexplained reduction of semen quality), after being treated with a daily dose of 12 µg recombinant follicle stimulating hormone (rFSH) for 6 months, can improve the chance of spontaneous pregnancy observed in their female partners in comparison to placebo (inactive treatment). For more information, please visit the trial\'s website www.adamclinicaltrial.com (only applicable in the US).
Epistemonikos ID: 2e6b1039bf02e23a1a7d317d3a67f591820b63dd
First added on: May 13, 2024